126 related articles for article (PubMed ID: 31612980)
21. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
22. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
[TBL] [Abstract][Full Text] [Related]
23. Metastatic colorectal cancer: current state and future directions.
Fakih MG
J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
25. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.
Seo MK; Cairns J
PLoS One; 2018; 13(9):e0204496. PubMed ID: 30256829
[TBL] [Abstract][Full Text] [Related]
26. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
[TBL] [Abstract][Full Text] [Related]
28. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
29. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
30. Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols.
Kovacevic A; Dragojevic-Simic V; Tarabar D; Rancic N; Jacimovic N; Katic J; Dagovic A; Jakovljevic M
Expert Rev Anticancer Ther; 2015; 15(8):963-70. PubMed ID: 26089093
[TBL] [Abstract][Full Text] [Related]
31. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
[TBL] [Abstract][Full Text] [Related]
32. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
34. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
37. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Cho SK; Hay JW; Barzi A
Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
[TBL] [Abstract][Full Text] [Related]
39. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
40. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
Zani S; Papalezova K; Stinnett S; Tyler D; Hsu D; Blazer DG
J Surg Oncol; 2013 Mar; 107(4):307-11. PubMed ID: 22811275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
